Objective: We evaluated associations between food insecurity (FI) and the quality and quantity of sleep in adults (≥18 years). Design: The current study represented a systematic review and meta-analysis of observational studies. Setting: Databases of PubMed, Scopus, Embase, and Web of Science were searched from inception until June 06, 2022. Meta-analyses were conducted using random-effects models, and effect sizes were reported as odds ratios (OR) and 95% confidence intervals (CI). Subjects: Data from ten eligible observational studies, including 83,764 participants, were included. Results: FI was associated with an increased risk of poor sleep quality (OR=1.45; 95% CI:1.24-1.70, I 2 =95, P<0.001, n=7). Besides, subgroup analysis showed increased risk of poor sleep quality corresponding to the severity of FI across mild (OR=1.31; 95% CI: 1.16-1.48, I 2 =0%, P<0.001, n=5), moderate (OR=1.49; 95% CI: 1.32-1.68, I 2 =0%, P<0.001, n=5), and severe (OR=1.89; 95% CI: 1.63-2.20, I 2 =0%, P<0.001, n=5) levels. Similarly, subgroup analysis by sleep problems showed that FI was associated with an increased the risk of trouble falling asleep (OR=1.39; 95% CI: 1.05-1.83, I 2 =91%, P=0.002, n=3) and trouble staying asleep (OR=1.91; 95% CI: 1.37-2.67, I 2 =89%, P<0.001, n=3). Moreover, FI was associated with the odds of shorter (OR=1.14; 95% CI:1.07-1.21, I 2 =0%, P<0.001, n=4) and longer sleep duration (OR=1.14; 95% CI:1.03-1.26, I 2 =0%, P=0.010, n=4). Conclusions: Collective evidence supports that FI is associated with poor sleep quality and quantity in adults. Preventative and management strategies that address FI may provide health benefits beyond improving nutritional status per se.

No abstract

Background This systematic review and dose–response meta-analysis of published randomized controlled trials (RCTs) was conducted to determine the effectiveness of camelina oil supplementation (COS) on lipid profiles and glycemic indices. Methods Relevant RCTs were selected by searching the ISI Web of Science, PubMed, and Scopus databases up to July 1, 2022. RTCs with an intervention duration of less than 2 weeks, without a placebo group, and those that used COS in combination with another supplement were excluded. Weighted mean differences and 95% confidence intervals were pooled by applying a random-effects model, while validated methods examined sensitivity analyses, heterogeneity, and publication bias. Results Seven eligible RCTs, including 428 individuals, were selected. The pooled analysis revealed that COS significantly improved total cholesterol in studies lasting more than 8 weeks and utilizing dosages lower than 30 g/d compared to the placebo group. The results of fractional polynomial modeling indicated that there were nonlinear dose–response relations between the dose of COS and absolute mean differences in low-density cholesterol, high-density cholesterol, and total cholesterol, but not triglycerides. It appears that the greatest effect of COS oil occurs at the dosage of 20 g/day. Conclusion The present meta-analysis indicates that COS may reduce cardiovascular disease risk by improving lipid profile markers. Based on the results of this study, COS at dosages lower than 30 g/d may be a beneficial nonpharmacological strategy for lipid control. Further RCTs with longer COS durations are warranted to expand on these results.

No abstract

Background Celiac disease (CD) is an autoimmune disease affecting around 1.4% of the total human population. Local and systemic manifestations are described in CD. Viral infections seem to trigger CD or even have a worse outcome in CD patients. The evidence on the relationship between CD and coronavirus disease (COVID-19) is limited. To evaluate existing evidence on the association between CD and COVID-19, we conducted the current systematic review. Methods We systematically searched Pubmed, Scopus, and Embase databases to find articles that reported risks or outcomes of COVID-19 in CD patients. Papers in any language published up to November 17, 2022, were evaluated for possible inclusion. The results were analyzed qualitatively. This study is registered with PROSPERO(CRD42022327380). Results We identified 509 studies by searching databases; 14 reported data on the risk or outcome of COVID-19 in CD patients and were eligible for qualitative synthesis. We found that the relative risk of acquiring COVID-19 in CD patients may be lower than in the general population. Approximately 90% of infected patients were treated as an outpatient, and 10% were hospitalized. GFD adherence and Health-related quality of life (HR-QOL) were more or less the same before and during the pandemic. The gluten-free products (GFP) supply seems to be plunged during the pandemic. The data on the psychological effects of the pandemic were conflicting. Conclusion The risk of acquiring COVID-19 in CD patients is lower than in the general population. Females were more likely to be infected by COVID-19, and the most common comorbidity in infected patients was a chronic lower respiratory disease; around 10% of infected patients needed hospitalization, GFD adherence, and HR-QOL was more or less the same before and during the pandemic, depression, anxiety, and stress levels of patients varied among studies. Patients had more difficulties accessing GFPs based on limited data.